Impact Therapeutics Inc:
Based in China, IMPACT is committed to the discovery and development of best-in-class therapeutics to treat cancer and other life-threatening diseases. IMPACT is a clinical-stage company with a unique small-molecule drug discovery and development platform targeting DDR. IMPACT's leading program, PARP inhibitor IMP4297, is currently undergoing phase I trials in Australia and China.
111 Xiangke Road
Building 3, Room 603
Pudong District, Shanghai, 200135
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.